Navigation Links
Burrill & Company Announces Promotions

SAN FRANCISCO, April 9 /PRNewswire/ -- Burrill & Company, a San Francisco based global leader in the life sciences with principal activities in Venture Capital, Private Equity, Merchant Banking and Media, is pleased to announce the following staff promotions:

Tiba Aynechi to Director, Merchant Banking

Garrett Vygantas, Director, Venture Capital

Neel Patel to Senior Associate, Merchant Banking

Tiba Aynechi joined Burrill Merchant Banking in 2006 following an internship in the Venture Group. Previously, Tiba was a postdoctoral fellow at the University of California, San Francisco, developing computational models for drug discovery. She received her Ph.D. from the Graduate Group in Biophysics at the University of California, San Francisco.

Garrett Vygantas - Before joining Burrill in 2006, Garrett was with Genentech's Market Planning Group where he focused on the commercialization and launch of Lucentis for the treatment of wet age-related macular degeneration. Dr. Vygantas completed his Transitional Residency at the University of Pennsylvania and holds M.D. and MBA degrees from Georgetown University. He is a co-founder and interim CEO of NewBridge Pharmaceuticals and serves on its Board of Directors. He is a Board Observer of Nora Therapeutics, Proventys, Ikano Therapeutics, ProteoGenix, and NanoVasc.

Neel Patel has broad advisory experience across life sciences coupled with functional experience in post-merger integration, turnaround management, operations and strategic planning. Neel was a management consultant with A.T. Kearney where he focused on strategy and operations consulting. He also worked in business development at Roche Diagnostics. He has an MBA from the University of Chicago Graduate School of Business.

"Our Merchant Banking and Venture Capital Practices continue to perform very well despite the difficult economic climate that we are currently facing. The promotions are reflective of the excellent contributions that these three individuals have made," said, G. Steven Burrill, CEO, Burrill & Company.

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the Burrill Report (, which tracks the progress of the global biotechnology industry; the Burrill Report Weekly Brief, and annual "State of the Industry" report the latest of which is Biotech 2009-Life Sciences: Navigating the Sea Change, the 23rd report on the industry. This book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond (

SOURCE Burrill & Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Burrill & Company Reacquires Burrill Life Sciences Media Group LLC
2. Biotech Finishes on a High in August, Burrill Report Says
3. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
4. New Sports Supplement Company to Partner with Indus Biotech
5. Sonic Innovations Celebrates Companys First Receiver-In-Canal Hearing Aid
6. Edmond Scientific Company Demonstrates RHIO/HIE Data Security and Privacy Solution for the NHIN at Annual HIMSS Conference, Chicago 09
7. Kashi Company Expands With New Island Vanilla(TM) Biscuit Cereal
8. TrinityCare Senior Living, Inc. Retains RJ Falkner & Company, Inc. as Investor Relations Counsel
9. Alivemax -- A Company Releasing Supplemental Products That Will Uplift the Health, Appearance, and Confidence of Others Around the Globe
10. Carriage Services Updates Company & Investment Profile
11. Anthem Blue Cross and Blue Shield, Eli Lilly and Company Establish Coalition to Help Improve the Health of Indiana Residents with Diabetes
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: